$2.72
-0.05-1.81%
At close: -
$3.00
0.2810.29%
After Hours: Dec 20, 7:05 PM EDT
Comments
Loading...
Latest news for Aclaris Therapeutics (NASDAQ:ACRS) Stock
Aclaris Therapeutics Stock (NASDAQ: ACRS)
Categories: All
Tuesday, November 19, 2024
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
- This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
- Leerink Partners Upgrades Aclaris Therapeutic...
- Jefferies Upgrades Aclaris Therapeutics to Bu...
- Aclaris Therapeutics shares are trading highe...
- BTIG Upgrades Aclaris Therapeutics to Buy, An...
Monday, November 18, 2024
Wednesday, November 06, 2024
Monday, October 28, 2024
Friday, October 25, 2024
Tuesday, September 17, 2024
Monday, August 19, 2024
Wednesday, August 07, 2024
Tuesday, July 23, 2024
Monday, July 22, 2024
Tuesday, July 16, 2024
Tuesday, July 09, 2024
Monday, July 08, 2024
Friday, June 14, 2024
Friday, May 24, 2024
Tuesday, May 07, 2024
Monday, May 06, 2024
Wednesday, March 06, 2024
Tuesday, February 27, 2024
Monday, January 22, 2024
- Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
- Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
- HC Wainwright & Co. Downgrades Aclaris Therap...
Tuesday, January 16, 2024
Thursday, January 11, 2024
Wednesday, January 10, 2024
- Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
- Crude Oil Falls 1%; Amarin Shares Spike Higher
- Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week
- Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial
- Dow Surges 100 Points; PriceSmart Earnings Top Views